What is Virpax Pharmaceuticals Inc's earnings per share (EPS)?

Virpax Pharmaceuticals Inc (VRPX) reported diluted earnings per share of $-2.84 for fiscal year 2024. This represents a 78.1% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Virpax Pharmaceuticals Inc Financials

VRPX

Source SEC Filings (10-K/10-Q) Updated Dec 31, 2024 Currency USD FYE December

This page shows Virpax Pharmaceuticals Inc (VRPX) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 5 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Financial Profile 5/100

Based on FY2024 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →

Health score ≠ stock price. This rates the quality of Virpax Pharmaceuticals Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Leverage

Virpax Pharmaceuticals Inc has elevated debt relative to equity (D/E of -2.70), meaning the company relies heavily on borrowed funds. This high leverage results in a low score of 21/100, reflecting increased financial risk.

Liquidity

Virpax Pharmaceuticals Inc's current ratio of 0.63 is below the typical benchmark, resulting in a score of 7/100. However, the company holds substantial cash reserves (61% of current liabilities), which buffers actual liquidity risk. Large mature operators often run tight current ratios by design.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

N/A

EBITDA

N/A

Net Income

N/A

EPS (Diluted)

$-2.84

YoY+78.1%

Virpax Pharmaceuticals Inc earned $-2.84 per diluted share (EPS) in fiscal year 2024. This represents an increase of 78.1% from the prior year.

Cash & Balance Sheet

Free Cash Flow

N/A

Cash & Debt

$1.5M

YoY-83.4%

Virpax Pharmaceuticals Inc held $1.5M in cash against $0 in long-term debt as of fiscal year 2024.

Dividends Per Share

N/A

Shares Outstanding

15M

YoY+27.1%

Virpax Pharmaceuticals Inc had 15M shares outstanding in fiscal year 2024. This represents an increase of 27.1% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

N/A

Capital Allocation

R&D Spending

$5.8M

YoY+13.7%

Virpax Pharmaceuticals Inc invested $5.8M in research and development in fiscal year 2024. This represents an increase of 13.7% from the prior year.

Share Buybacks

N/A

Capital Expenditures

N/A

VRPX Income Statement

Metric	FY24	FY23	FY22	FY21	FY20
Revenue	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$5.8M+13.7%	$5.1M-52.5%	$10.8M+122.4%	$4.8M+274.7%	$1.3M
SG&A Expenses	$6.3M-40.8%	$10.6M-4.6%	$11.1M+54.2%	$7.2M	N/A
Operating Income	N/A	-$15.7M+28.2%	-$21.8M-81.7%	-$12.0M	N/A
Interest Expense	$104K	N/A	N/A	$93K-37.3%	$148K
Income Tax	N/A	N/A	N/A	N/A	N/A
Net Income	N/A	-$15.2M+29.8%	-$21.7M-79.6%	-$12.1M	N/A
EPS (Diluted)	$-2.84+78.1%	$-12.97	$-18.49	$-1.81	N/A

Metric	Q4'24	Q3'24	Q2'24	Q1'24	Q4'23	Q3'23	Q2'23	Q1'23
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	N/A	$1.1M-41.5%	$2.0M+21.2%	$1.6M	N/A	$1.5M+15.9%	$1.3M+4.5%	$1.2M
SG&A Expenses	N/A	$781K-48.0%	$1.5M-11.1%	$1.7M	N/A	$4.6M+137.1%	$1.9M+369.1%	$415K
Operating Income	N/A	N/A	-$3.5M-4.7%	-$3.3M	N/A	-$6.1M-88.8%	-$3.2M-96.2%	-$1.7M
Interest Expense	N/A	$93K+743.0%	$11K	N/A	N/A	$0	N/A	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	N/A	N/A	-$3.5M-7.1%	-$3.2M	N/A	-$6.0M-92.6%	-$3.1M-104.7%	-$1.5M
EPS (Diluted)	N/A	$-0.43+75.4%	$-1.75	$-2.75	N/A	$-5.12-92.5%	$-2.66-104.6%	$-1.30

VRPX Balance Sheet

Metric	FY24	FY23	FY22	FY21	FY20
Total Assets	$1.6M-83.8%	$9.6M-51.1%	$19.7M-50.3%	$39.6M+8402.8%	$465K
Current Assets	$1.6M-83.8%	$9.6M-51.1%	$19.7M-50.3%	$39.6M+54057.6%	$73K
Cash & Equivalents	$1.5M-83.4%	$9.1M-51.9%	$19.0M-48.4%	$36.8M+67134.8%	$55K
Inventory	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$2.5M-67.9%	$7.7M+148.6%	$3.1M+48.2%	$2.1M-55.4%	$4.7M
Current Liabilities	$2.5M-67.9%	$7.7M+148.6%	$3.1M+48.2%	$2.1M-43.0%	$3.7M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A
Total Equity	-$914K-147.2%	$1.9M-88.3%	$16.6M-55.8%	$37.5M+989.1%	-$4.2M
Retained Earnings	-$71.6M-20.3%	-$59.5M-34.2%	-$44.4M-95.4%	-$22.7M-113.2%	-$10.6M

Metric	Q4'24	Q3'24	Q2'24	Q1'24	Q4'23	Q3'23	Q2'23	Q1'23
Total Assets	$1.6M+411.4%	$304K-88.3%	$2.6M-17.2%	$3.1M-67.5%	$9.6M-26.2%	$13.0M-18.3%	$16.0M-13.7%	$18.5M
Current Assets	$1.6M+411.4%	$304K-88.3%	$2.6M-17.2%	$3.1M-67.5%	$9.6M-26.2%	$13.0M-18.3%	$16.0M-13.7%	$18.5M
Cash & Equivalents	$1.5M+8682.0%	$17K-99.1%	$1.9M+0.2%	$1.9M-79.6%	$9.1M-24.8%	$12.2M-17.9%	$14.8M-12.9%	$17.0M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$2.5M+4.8%	$2.4M-56.3%	$5.4M+24.0%	$4.3M-43.5%	$7.7M+17.8%	$6.5M+79.1%	$3.6M+10.7%	$3.3M
Current Liabilities	$2.5M+4.8%	$2.4M-56.3%	$5.4M+24.0%	$4.3M-43.5%	$7.7M+17.8%	$6.5M+79.1%	$3.6M+10.7%	$3.3M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	-$914K+55.5%	-$2.1M+26.6%	-$2.8M-130.3%	-$1.2M-162.7%	$1.9M-70.3%	$6.5M-47.1%	$12.3M-19.0%	$15.2M
Retained Earnings	-$71.6M-5.0%	-$68.2M-3.0%	-$66.2M-5.5%	-$62.8M-5.4%	-$59.5M-8.3%	-$55.0M-12.2%	-$49.0M-6.8%	-$45.9M

VRPX Cash Flow Statement

Metric	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	N/A	-$9.9M+44.8%	-$17.8M-22.7%	-$14.5M-950.1%	-$1.4M
Capital Expenditures	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	N/A	N/A	N/A	N/A	N/A
Financing Cash Flow	N/A	N/A	N/A	$51.3M+3571.3%	$1.4M
Dividends Paid	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A

Metric	Q4'24	Q3'24	Q2'24	Q1'24	Q4'23	Q3'23	Q2'23	Q1'23
Operating Cash Flow	-$2.9M	N/A	-$1.6M+78.7%	-$7.7M-156.7%	-$3.0M-13.6%	-$2.7M-21.4%	-$2.2M-8.7%	-$2.0M
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Financing Cash Flow	$4.4M	N/A	$1.6M+263.1%	$454K	N/A	N/A	N/A	N/A
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

VRPX Financial Ratios

Metric	FY24	FY23	FY22	FY21	FY20
Gross Margin	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	-785.3%-654.7pp	-130.6%-98.4pp	-32.2%	N/A
Return on Assets	N/A	-157.8%-47.7pp	-110.0%-79.6pp	-30.5%	N/A
Current Ratio	0.63-0.6	1.25-5.1	6.36-12.6	18.96+18.9	0.02
Debt-to-Equity	-2.70-6.7	3.98+3.8	0.19+0.1	0.06+1.2	-1.11
FCF Margin	N/A	N/A	N/A	N/A	N/A

Metric	Q4'24	Q3'24	Q2'24	Q1'24	Q4'23	Q3'23	Q2'23	Q1'23
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	N/A	N/A	N/A	N/A	-92.1%-66.8pp	-25.3%-15.3pp	-10.0%
Return on Assets	N/A	N/A	-133.2%-30.3pp	-102.9%	N/A	-46.0%-26.5pp	-19.5%-11.3pp	-8.2%
Current Ratio	0.63+0.5	0.13-0.4	0.48-0.2	0.72-0.5	1.25-0.7	2.00-2.4	4.37-1.2	5.61
Debt-to-Equity	-2.70-1.6	-1.15+0.8	-1.93+1.7	-3.58-7.6	3.98+3.0	1.00+0.7	0.30+0.1	0.22
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Note: Shareholder equity is negative (-$914K), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.

Note: The current ratio is below 1.0 (0.63), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.

Similar Companies

Biostax Corp BTAX

$16K

Scopus Biopharma Inc. SCPS

$13K

Renovacare RCAR

$9K

Q Biomed QBIO

$15K

Statera Biopharma Inc STAB

$7K

Frequently Asked Questions

What are Virpax Pharmaceuticals Inc's total assets?

Virpax Pharmaceuticals Inc (VRPX) had $1.6M in total assets as of fiscal year 2024, including both current and long-term assets.

How much does Virpax Pharmaceuticals Inc spend on research and development?

Virpax Pharmaceuticals Inc (VRPX) invested $5.8M in research and development during fiscal year 2024.

How many shares does Virpax Pharmaceuticals Inc have outstanding?

Virpax Pharmaceuticals Inc (VRPX) had 15M shares outstanding as of fiscal year 2024.

What is Virpax Pharmaceuticals Inc's current ratio?

Virpax Pharmaceuticals Inc (VRPX) had a current ratio of 0.63 as of fiscal year 2024, which is below 1.0, which may suggest potential liquidity concerns.

What is Virpax Pharmaceuticals Inc's debt-to-equity ratio?

Virpax Pharmaceuticals Inc (VRPX) had a debt-to-equity ratio of -2.70 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.

Why is Virpax Pharmaceuticals Inc's debt-to-equity ratio negative or unusual?

Virpax Pharmaceuticals Inc (VRPX) has negative shareholder equity of -$914K as of fiscal year 2024, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.

How financially healthy is Virpax Pharmaceuticals Inc?

Virpax Pharmaceuticals Inc (VRPX) scores 5 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.